M Sideri

IEO - Istituto Europeo di Oncologia, Milano, Lombardy, Italy

Are you M Sideri?

Claim your profile

Publications (72)178.01 Total impact

  • Mario Sideri
    Surgical Oncology 12/2010; 19(4):247-247. DOI:10.1016/j.suronc.2009.05.001 · 2.37 Impact Factor
  • Source
    Ultrasound in Obstetrics and Gynecology 10/2010; 36(S1):49. DOI:10.1002/uog.7918 · 3.14 Impact Factor
  • Source
    Ultrasound in Obstetrics and Gynecology 10/2010; 36(S1):143. DOI:10.1002/uog.8219 · 3.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To test the efficacy of levonorgestrel-release intrauterine device (LNG-IUD) plus gonadotropin-releasing hormone (GnRH) for treating women aged <40 years with atypical endometrial hyperplasia (AEH) or presumed International Federation of Gynecology and Obstetrics stage IA limited to the endometrium, well differentiated (G1), endometrioid endometrial cancer (EC), who wish to preserve their fertility. A prospective observational study was conducted. Treatment consisted on the insertion of an LNG-IUD for 1 year plus GnRH analogue for 6 months. From January 1996 to June 2009, 20 and 14 patients with AEH and EC, respectively, were studied. Complete response rate was 95% in patients with AEH and 57.1% in women with EC-G1. A progression of the disease was observed in one (5%) and in four patients (28%) with AEH and EC, respectively. Four of 20 patients with AEH and 2 of 14 with EC-G1 experienced recurrences. The average relapse time was 36 months (range: 16-62 months). All of them were alive without evidence of disease at the last follow-up, mean: 29 months (range: 4-102 months). Nine women achieved 11 spontaneous pregnancies. The combined treatment showed effectiveness in a substantial proportion of patients with AEH and EC. Close follow-up during and after treatment is crucial.
    Annals of Oncology 09/2010; 22(3):643-9. DOI:10.1093/annonc/mdq463 · 6.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Global Objective: The Home Study Course is intended for the practicing colposcopist or practitioner who is seeking to develop or enhance his/her colposcopic skills. The goal of the course is to present colposcopic cases that are unusual or instructive in terms of appearance, presentation, or management or that demonstrate new and important knowledge in the area of colposcopy or pathology. Participants may benefit from reading and studying the material or from testing their knowledge by answering the questions. Target Audience: Target learners for Home Study Courses are colposcopists in clinical practice and may include gynecologists, family physicians, pathologists, residents in training in any one of these specialties, gynecologic oncologists, and mid-level providers such as nurse practitioners, physician's assistants, and certified nurse midwives. ACCME Accreditation: The ASCCP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Credit: The ASCCP designates this education activity for a maximum of 1 AMA PRA Category I Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Management of Conflicts of Interest and Contributed Funds: As an accredited provider of continuing medical education credit, the American Society for Colposcopy and Cervical Pathology (ASCCP) is required to comply with the Accreditation Council for Continuing Medical Education's Standards of Commercial Support and has implemented a management process to ensure that anyone who is in a position to affect the content of the educational activity (e.g., authors, planners, etc.) has disclosed to us all relevant financial relationships with any commercial interest and has ensured that those relationships do not influence the presentation materials. All authors have agreed to base their presentations on best available evidence. The ASCCP discloses to learners any financial relationship(s) to health care-related commercial interests existing within the past 12 months to include the following information: (1) the name of the individual, (2) the name of the commercial interest, and (3) the nature of the relationship the person has with each commercial interest. The Editor reviews the case-study materials for possible bias, and potential conflicts of interest are resolved before the formal submission to the Journal for publication. Any discussion of off-label use of products is noted when appropriate, as is discussion of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Disclosures of these commitments and/or relationships are published immediately before the presentation of the case-study materials so those learners intending to participate in the activity may formulate their own judgments regarding the presentation. Under ASCCP policy, a Home Study Course will not be accepted from an author who does not agree to either disclose or amend material to eliminate potential bias identified by the Editor. Disclosures: Lori Lowe, MD (author), R. Kevin Reynolds, MD (author), Mario Sideri, MD (author), L. Stewart Massad, MD (Accreditation and Enduring Materials Chair), Amy E. Mason (Home Study Course Staff Administrator), Kathleen G. Poole (ASCCP, Executive Director), Thomas M. Julian, MD (Journal of Lower Genital Tract Disease Executive Editor), and Sandra Smith (Journal of Lower Genital Tract Disease Administrative Assistant to the Editor) have no such financial relationship or conflict of interest to report. Hope K. Haefner, MD (author): Merck & Co., Inc. (speakers' bureau, honorarium). Mark Spitzer, MD (Home Study Course Editor): Merck & Co., Inc. (honorarium); Elsevier (book author, royalty); speakers' bureau, consultant; SABK (book author, royalty). Disclaimer: The clinical history and images in the Home Study Course may represent an actual case, but not always. To improve educational quality, some gross, cytological, or histological images may come from photographic libraries. Good teaching cases are often difficult to obtain, and we encourage our readers to submit cases with high-quality images to the Home Study Course Editor or Executive Editor to consider for publication. Acknowledgment: Images courtesy of Hope K. Haefner, MD, and Lori Lowe, MD.
    Journal of Lower Genital Tract Disease 09/2009; 13(4):269-274. DOI:10.1097/LGT.0b013e3181b81788 · 1.11 Impact Factor
  • Source
    Ultrasound in Obstetrics and Gynecology 09/2009; 34(S1):140. DOI:10.1002/uog.6890 · 3.14 Impact Factor
  • Source
    Ultrasound in Obstetrics and Gynecology 08/2008; 32(3):285-286. DOI:10.1002/uog.5539 · 3.14 Impact Factor
  • Source
    Ultrasound in Obstetrics and Gynecology 10/2007; 30(4):436 - 436. DOI:10.1002/uog.4332 · 3.14 Impact Factor
  • Source
    Ultrasound in Obstetrics and Gynecology 09/2006; 28(4):405 - 405. DOI:10.1002/uog.3017 · 3.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lymph node pathologic status is the most important prognostic factor in vulvar cancer; however, complete inguinofemoral node dissection is associated with significant morbidity. Lymphoscintigraphy associated with gamma-probe guided surgery reliably detects sentinel nodes in melanoma and breast cancer patients. This study evaluates the feasibility of the surgical identification of sentinel groin nodes using lymphoscintigraphy and a gamma-detecting probe in patients with early vulvar cancer. Technetium-99m-labelled colloid human albumin was administered perilesionally in 37 patients with invasive epidermoid vulvar cancer (T1-T2) and lymphoscintigraphy performed the day before surgery. An intraoperative gamma-detecting probe was used to identify sentinel nodes during surgery. A complete inguinofemoral node dissection was then performed. Sentinel nodes were submitted separately to pathologic evaluation. A total of 55 groins were dissected in 37 patients. Localization of the SN was successful in all cases. Eight cases had positive nodes: in all the sentinel node was positive; the sentinel node was the only positive node in five cases. Twenty-nine patients showed negative sentinel nodes: all of them were negative for lymph node metastases. Lymphoscintigraphy and sentinel-node biopsy under gamma-detecting probe guidance proved to be an easy and reliable method for the detection of sentinel node in early vulvar cancer. This technique may represent a true advance in the direction of less aggressive treatments in patients with vulvar cancer.
    British Journal of Cancer 02/2000; 82(2):295-9. DOI:10.1054/bjoc.1999.0918 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pathologic lymph node status is the most important prognostic factor in vulvar cancer; however, complete inguinofemoral node dissection is associated with significant morbidity. Intraoperative lymphoscintigraphy associated with gamma detecting probe-guided surgery has proved to be reliable in the detection of sentinel node (SN) involvement in melanoma and breast cancer patients. The present study evaluates the feasibility of the surgical identification of inguinal sentinel nodes using lymphoscintigraphy and a gamma detecting probe in patients with early vulvar cancer. Technetium-99-labeled colloid human albumin was administered perilesionally in 44 patients. Twenty patients had T1 and 23 had T2 invasive epidermoid vulvar cancer; one patient had a lower-third vaginal cancer. An intraoperative gamma detecting probe was used to identify SNs during surgery. Complete inguinofemoral node dissection was subsequently performed. SNs underwent separate pathologic evaluation. A total of 77 groins were dissected in 44 patients. SNs were identified in all the studied groins. Thirteen cases had positive nodes: the SN was positive in all of them; in 10 cases the SN was the only positive node. Thirty-one patients showed negative SNs: all of them were negative for lymph node metastasis. Lymphoscintigraphy and SN biopsy under gamma detecting probe guidance proved to be an easy and reliable method for detection of SNs in early vulvar cancer. If these preliminary data will be confirmed, the technique would represent a real progress towards less aggressive treatment in patients with vulvar cancer.
    Tumori 01/2000; 86(4):359-63. · 1.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite improvements seen in median and overall survival using a combination of platinum-compounds and paclitaxel (PTX), long-term survival rates for patients with advanced epithelial ovarian carcinoma remain disappointing and ongoing efforts have aimed to develop more effective primary therapy. In the early 1990Os the drug PTX was first tested in ovarian cancer. In the Gynaecological Oncology Group (GOG) trial 111 the cisplatin (CP)+PTX regimen was judged to be superior compared to the platinum-based control arm with an improvement of overall response rate, median progression-free interval and overall median survival. These favourable data were confirmed by a European-Canadian Intergroup trial (OV10). In contrast, in a further GOG trial (GOG132) there was no difference in survival between CP alone and the combination of PTX and CP. The International Collaborative Ovarian Neoplasm Study (ICON)3 is the first and only trial comparing PTX plus carboplatin against carboplatin alone or a (non-taxane) CP-based control arm. The last analysis performed with a total of 1,293 events showed an estimated absolute difference in one-year progression-free survival of 1% and in two-year overall survival of 2% both in favour of PTX plus carboplatin. The results of ICON3, in accordance with GOG132 study, appear to contradict the earlier positive results seen for PTX and CP in the GOG-111 and OV10 trials and suggested that single agent carboplatin, CY-adriamycin-CP are safe and effective first-line treatments for women requiring chemotherapy for ovarian cancer. A meta-analysis with individual patient data is warranted to better clarify the issue of PTX in the front line therapy of advanced ovarian cancer. Salvage chemotherapy is often utilised in patients with advanced ovarian cancer, due to the high frequency of recurrent disease even after a clinical or pathological complete response after primary chemotherapy. Main objectives of salvage chemotherapy include: i. improvement in quality of life and symptoms; ii. tumour load reduction and survival advantage; iii. evaluation of potentially active new drugs to be included in first-line. Since the goal is palliation in most cases, monotherapy is generally indicated. However, the chances of response are directly related to the treatment-free interval, with a response rate nearly equivalent to that of primary chemotherapy when the treatment-free interval exceeds 24 months. Extension of the platinum-free interval before re-treatment with platinum or taxanes may allow partial reversal of resistance to these agents which can therefore still show significant activity in relapsing patients. Unfortunately, durable response to salvage chemotherapy is rare and cure is almost impossible. The sequential use of the agents currently available for salvage treatment in monotherapy may transform ovarian cancer into a chronic disease and confers long survival to the patients. Perhaps, the most interesting role of second-line chemotherapy is to identify new potentially active drugs, which can be moved up-front. Most of the compounds used in second line (gemcitabine, topotecan, liposomal doxorubicin) are in fact under investigation to develop alternative schedules and sequences of drug administration. A new phase III multi-national randomised study for patients with advanced stage epithelial ovarian or primary periperitoneal carcinoma will evaluate the impact of incorporating a new drug within either a platinum-based triplet (new drug + platinum + PTX) or a sequential-doublet (new drug + platinum followed by platinum + PTX) in order to identify one or more experimental regimens able to improve long-term survival with acceptable toxicity.
    Forum (Genoa, Italy) 01/2000; 10(4):323-32.
  • Critical Reviews in Oncology/Hematology 01/2000; 32(3):221-8. DOI:10.1016/S1040-8428(99)00049-9 · 4.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Our objective was to evaluate the results of laser surgery in patients with vulvar intraepithelial neoplasia (VIN). From January 1990 to December 1996, 52 patients with histologically proven VIN were treated with CO(2) laser vaporization or laser excision. The analysis included anamnestic characteristics, clinical aspects, types of treatment, correlation of the preoperative biopsy with the excised pathologic specimen, and follow-up results. Fourteen women underwent laser vaporization, and 38, laser excision. Of the patients submitted to vaporization, 11 were cured in one session (75%), 1 required two procedures, and 2 other patients, who underwent more treatments, eventually developed invasive squamous cell cancer 5 and 7 years from the initial treatment. The cure rate for laser excision was better, as a single session of treatment was curative in 33 of 38 patients (87%). In 3 cases the pathology report on the excised specimen showed an unrecognized invasive lesion (12%) and the women underwent radical surgery. The 2 remaining patients, both affected by multifocal disease, experienced recurrences and were treated with laser excision 2 and 3 years after the primary treatment, respectively. Symptom relief was obtained in all patients studied with both laser vaporization and excision. Excisional laser surgery is an effective treatment for patients with VIN. In addition, CO(2) laser excision allows evaluation of the operative specimen and detection of occult early invasion with good preservation of vulvar morphology; laser vaporization, while retaining good cosmetic results, is less effective in VIN treatment and does not allow evaluation of the surgical specimen.
    Gynecologic Oncology 12/1999; 75(2):277-81. DOI:10.1006/gyno.1999.5584 · 3.69 Impact Factor
  • Journal of Lower Genital Tract Disease 01/1999; 3(1). DOI:10.1097/00128360-199901000-00012 · 1.11 Impact Factor
  • Journal of Lower Genital Tract Disease 01/1999; 3(1). DOI:10.1097/00128360-199901000-00033 · 1.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to compare the use of molecular hybridization by hybrid capture methodology for human papillomavirus (HPV) with the use of demographic and lifestyle variables as intermediate triage in patients with cytological mild dyskaryosis. The study was designed as a prospective study using regression tree analysis of demographic data in consecutive patients who were subjected to colposcopic evaluation at the colposcopy clinic at the First Department of Obstetrics and Gynaecology, University of Milan (Milan, Italy). A total of 177 women were subjected to colposcopy because of a single routine Pap smear showing mild dyskaryosis. A structured interview, sampling for HPV testing for the detection of viral DNA by hybrid capture methodology, and colposcopic evaluation with cervical biopsies were performed for each subject. The accuracies of molecular hybridization for HPV and of the classification model based on the demographic and lifestyle variables in predicting patients with histologically high-grade cervical intraepithelial lesions were measured. The classification model based on the demographic and lifestyle variables showed comparable results with molecular hybridization for HPV (specificity, 0.75 versus 0.73; sensitivity, 0.61 versus 0.67, respectively). The use of demographic and lifestyle variables appears to be a simple and economic possibility for triaging patients with mild dyskaryotic smears in a screening program.
    Cancer Epidemiology Biomarkers & Prevention 03/1998; 7(3):237-41. · 4.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of vulvar lichen sclerosus has greatly improved in recent years, with the introduction of new pharmacological approaches and reconsideration of the traditional ones. Oxatomide is a molecule with both antihistamine and inhibiting activities for the inflammatory response, which may have potential use against this disease. We enrolled 22 patients affected by vulvar lichen sclerosus in a double-blind, cross-over, controlled trial. They were administered a 5% oxatomide-based gel formulation and a placebo (petrolatum ointment) topically. At the beginning and the end of the investigation the severity and duration of symptoms, clinical appearance and tolerability were recorded. Statistical analysis of data was performed by Fisher's exact test and the Student-Newman-Keuls test. The results indicate that both regimens are significantly correlated with vulvar pruritus improvement and that 5% oxatomide gel has better anti-itching effects compared to the placebo. Other symptoms responded poorly to the treatment. The rate of complete-partial regression of pruritus was significantly higher (P < 0.05) in the oxatomide group than in controls, while no significant improvement was obtained neither with oxatomide or with placebo in terms of clinical appearance. These results, adequately confirmed, could suggest the introduction of oxatomide, in selected patients, as an alternative for the treatment of vulvar lichen sclerosus.
    International Journal of Gynecology & Obstetrics 12/1996; 55(3):259-64. DOI:10.1016/S0020-7292(96)02768-3 · 1.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine interoperator variability in the colposcopic evaluation of patients with mild dysplastic smears, retrospective comparison of colposcopy and biopsy results in 856 patients examined by 11 colposcopists in the Outpatient Colposcopy Clinic of "L. Mangiagalli" Institute, Milano, was performed. The patients underwent a complete colposcopic assessment and target biopsy on suspect areas if a screening smear showed mild dysplasia. Colposcopic findings and disease detection rate for each operator were compared. There was no significant (P > 0.05) difference in the recording of abnormal colposcopic findings. Significant differences were found, however, in abnormal transformation zone grading (P < 0.001), biopsy rate (P < 0.05), and squamocolumnar junction visualization (P < 0.005). There was no significant difference in overall disease detection (P > 0.5) but there was a statistically significant, inverse relation (r = -0.6, P < 0.01) between the high grade (cervical intraepithelial neoplasia grades 2 and 3) and low grade (human papillomavirus/cervical intraepithelial neoplasia grade 1) detection rate for each operator. High grade disease detection in patients with mild dysplastic smears is influenced the subjectivity of the colposcopic examination. This should be considered when planning optimal management for patients with mild dysplasia.
    Cancer 12/1995; 76(9):1601-5. · 4.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To identify the epidemiologic characteristics of women who have mild dyskaryosis on cervical smear but cervical intraepithelial neoplasia (CIN) grade II or III at biopsy. We analyzed information from 291 women (median age 33 years, range 17-69) observed for the first time with a single smear test showing mild dyskaryosis. All subjects underwent colposcopy, and histologic confirmation was obtained by biopsy. We compared the characteristics of women who had CIN I or no evidence of CIN with those of women with CIN II or III at biopsy. Twenty-eight women (10%) had CIN I at biopsy, 46 (15%) CIN II, and 23 (8%) CIN III. The frequency of CIN II or III tended to decrease with increasing education; compared with women reporting 11 or fewer years of education, the multivariate odds ratios (OR) of CIN II or III lesions was 0.5 (95% confidence interval [CI] 0.3-0.9) in those reporting 11 years of education or more. Compared with nulliparas, the OR of CIN II or III was 1.8 (95% CI 1.1-3.5) for parous women. Furthermore, compared with never-smokers, the OR of CIN II or III was 2.3 (95% CI 1.0-5.4) for current smokers. Ex-smokers were at increased risk, too; the estimated multivariate OR was 3.8 (95% CI 1.9-7.6). Compared with women reporting one sexual partner, the multivariate ORs of CIN II or III were 1.4 and 2.3 for women reporting two to three or four or more sexual partners, respectively (chi 2(1) trend = 6.65, P < .05). Our results show that smoking is a risk indicator of CIN II or III in women with a single smear showing mild dyskaryosis. Parous women, those of low social standing, and those reporting multiple sexual partners also are at increased risk of CIN II or III.
    Obstetrics and Gynecology 11/1995; 86(5):754-7. DOI:10.1016/0029-7844(95)00281-U · 4.37 Impact Factor

Publication Stats

637 Citations
178.01 Total Impact Points


  • 1999–2015
    • IEO - Istituto Europeo di Oncologia
      • Division of Preventive Gynecology
      Milano, Lombardy, Italy
  • 2013
    • Parc de Salut Mar
      Barcino, Catalonia, Spain
  • 1983–1998
    • University of Milan
      Milano, Lombardy, Italy
  • 1995
    • Mario Negri Institute for Pharmacological Research
      • Department of Epidemiology
      Milano, Lombardy, Italy
  • 1982
    • INO - Istituto Nazionale di Ottica
      Florens, Tuscany, Italy